Patritumab deruxtecan
Patritumab deruxtecan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Breast Neoplasms。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
16 项
全球在招研究
1 项
已进入 III/IV 期
30 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Merck Sharp & Dohme LLC
- QuantumLeap Healthcare Collaborative
- Daiichi Sankyo
- Gustave Roussy, Cancer Campus, Grand Paris
- The Netherlands Cancer Institute
- Samsung Medical Center
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Chile、Greece、Hungary、Israel、意大利、Poland、西班牙、中国台湾、Turkey (Türkiye)、Ukraine、比利时
正在招募患者的 Patritumab deruxtecan 研究
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
II 期招募中美国ChileGreeceHungaryNCT06731907A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
I 期 / II 期招募中美国比利时法国意大利NCT07701941KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
I 期 / II 期招募中美国加拿大HungaryIsraelNCT04165070A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
I 期 / II 期招募中美国BrazilChile中国NCT07286149Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
I 期 / II 期招募中美国BrazilChile中国NCT06469944Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
I 期 / II 期招募中法国NCT06298084Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
II 期招募中荷兰NCT06222489Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
II 期招募中美国South Korea西班牙中国台湾NCT06797635Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
II 期招募中South KoreaNCT06383884Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
I 期 / II 期招募中美国加拿大Israel日本NCT06686394A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
II 期招募中美国澳大利亚比利时加拿大NCT06172478A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
I 期 / II 期招募中美国澳大利亚比利时BrazilNCT06941272Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
II 期招募中法国NCT04965766Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
I 期 / II 期招募中美国BrazilChile中国NCT06445972A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
III 期招募中美国Argentina澳大利亚BrazilNCT07060807
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。